Postmarketing Studies Face Continued Scrutiny Despite Cleaned-Up Database
Executive Summary
Drug makers that have put off starting post-market studies under FDA oversight can no longer count on the agency's messy database to provide cover for their dawdling
You may also be interested in...
Scrutiny Urged For FDA Divisions With High Number Of Delayed Postmarketing Studies
Postmarketing studies are more likely to be delayed in some Center for Drug Evaluation and Research review divisions than others, and one of FDA’s consultants wants the agency to find out why.
Scrutiny Urged For FDA Divisions With High Number Of Delayed Postmarketing Studies
Postmarketing studies are more likely to be delayed in some Center for Drug Evaluation and Research review divisions than others, and one of FDA’s consultants wants the agency to find out why.
GAO Questions FDA's Handling Of Surrogate Endpoints
FDA should develop guidance delineating when it would withdraw products that have been cleared under the accelerated approval mechanism, according to a report from the Government Accountability Office